01:43 PM EDT, 09/10/2024 (MT Newswires) -- UnitedHealth Group ( UNH ) is joining other large US pharmacy benefit managers in excluding AbbVie's ( ABBV ) Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, Reuters reported Tuesday, citing the company.

Instead, the company will recommend less expensive biosimilar versions of the medicine to patients, including Amgen's ( AMGN ) Amjevita, the report said.

The company said it will be possible for for patients to get coverage for Humira until the US Food and Drug Administration designates the preferred biosimilars on its plans as interchangeable. The regulator is reportedly expected to grant the designation in 2025.

UnitedHealth Group ( UNH ), AbbVie ( ABBV ), Amgen ( AMGN ), and the US FDA did not immediately respond to requests for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 602.24, Change: +8.14, Percent Change: +1.37